

*ERS Research Seminar*  
***Lung Cancer Screening: from Trial to Practice***  
*11 – 12 December 2018*  
*Barcelona, Spain*

**Tuesday, 11 December 2018**

08.15 – 08.30 Registration

08.30 – 08.45 Introduction and welcome  
*Jan van Meerbeeck and Annemie Snoeckx*

**Session I – Lung cancer screening: what do we know, what don't we know**

*Chairs: Guido van Hal*

08.45 – 09.15 NELSON: the Trafalgar of lung cancer screening?  
*Harry De Koning (Netherlands)*

09.15 – 09.45 View from the public health bench  
- TBC

09.45 – 10.15 General discussion

10.15 – 10.30 *Coffee break*

**10.30 – 11.30: Session II – Break out session 1: define per country or per 2 countries**

*1: How is screening of cancer in general organized in your country?*

*2: Who are the stakeholders for lung cancer screening implementation in your country?*

*3: What are the necessary steps for lung cancer screening implementation in your country?*

11.30 – 12.15 Plenary report of break out groups

*Chairs: Mina Gaga and Torsten Blum*

12.15 – 13.00 *Lunch Break*

**Session III – Implementation in Europe: hurdles and steps**

*Chairs: John Field and Annemie Snoeckx*

13.00 – 13.20 Participation in screening: lessons learned from the past  
*Guido Van Hal (Belgium)*

13.20 – 13.40 Public understanding and informed decision making: keys to a successful screening programme  
*David Ritchie (Belgium)*

13.40 – 14.00 How to best target the hard-to-reach? The UK-experience?  
*Samantha Quaiife (UK)*

14.00 – 14.20 The role of patient advocacy groups in implementation  
*Bert van Herk (Netherlands)*

14.20 – 14.45 Where does the EU go from here?  
*EU commissioner DG Health and Consumer Protection*

14.45 – 15.30 General discussion

15.30 – 16.00            *Coffee break*

**Session IV – Risk assessment strategies**

*Chairs: Harry De Koning and Torsten Blum*

16.00 – 16.20            Risk assessment scores: a critical appraisal  
*Hans-Ulrich Kauczor (Germany)*

16.20 – 16.40            Breathomics as a possible risk stratification tool to augment lung cancer screening  
*Marc van der Schee (Netherlands)*

16.40 – 17.00            Blood biomarkers: ready for practice?  
*John Field (UK)*

17.00 – 17.45            Discussion

17.45 – 18.00            Summary of the day /introduction to day 2  
*Jan van Meerbeeck (Belgium)*

**Wednesday, 12 December 2018**

08.30 – 10.00    **Session V – Break out session 2: standardisation**

*Group 1: Recruitment implementation - Chair: Jan van Meerbeeck*

*Can we define a minimum common risk assessment strategy for Europe?*

*Group 2: Technical implementation - Chairs Annemie Snoeckx and Hans-Ulrich Kauczor*

*Can we define a common minimal SOP for nodule handling and follow up?*

10.00 – 10.30            *Coffee break*

10.30 – 11.00    Report from break out groups  
*Chairs: David Baldwin and Hans-Ulrich Kauczor*

**Session VI – From trial to practice: concerns of different stakeholders**

*Chairs: John Field and Hans-Ulrich Kauczor*

11.00 – 11.20            How will lung cancer screening impact our daily practice? A radiologist's view  
*Annemie Snoeckx (Belgium)*

11.20 – 11.40            Artificial Intelligence: an extra clinician we can not ignore  
*Bram Van Ginneken (Netherlands)*

11.40 – 12.00            The surgeon's point of view  
*Herbert Decaluwé (Belgium)*

12.00 – 12.30            General discussion

12.30 – 13.00            *Summing up: remarks, conclusions and action points*

13.00 – 14.00            *Lunch and farewell*

14.00 – 15.00            **Private meeting – KOL's prepare summary of the meeting**  
Finalizing the ESR-ERS White paper on screening  
Finalizing the White paper co-authors